von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: A prospective multicenter trial in elective surgery

Stefan Lethagen, P. A. Kyrle, G. Castaman, S. Haertel, P. M. Mannucci, G. Auerswald, J. Batlle, G. Castaman, P. Collins, É D'Amico, H. Dasani, A. B. Federici, W. Hassenpflug, C. Heller, F. Hernández-Navarro, M. Holmström, Jørgen Ingerslev, D. Keeling, J. Klinge, M. KrauseW. Kreuz, P. A. Kyrle, F. López Fernández, C. A. Ludlam, P. M. Mannucci, W. Miesbach, J. Monteagudo, E. W. Muntean, C. Négrier, P. Petrini, M. Quintana Molina, H. Ramschak, J. C. Reverter, I. Scharrer, R. Schneppenheim, S. Schulman, J. F. Schved, F. Scognamiglio, A. Siebenhofer, T. Spranger, D. Tàssies, Sandra Vallin, A. Villar Camacho, M. V Depka Prondzinski, V. Weltermann

Research output: Contribution to journalArticlepeer-review

Abstract

Background: While plasma-derived concentrates containing large amounts of von Willebrand factor (VWF) are effective in treating von Willebrand disease (VWD), optimal dosing remains to be fully characterized. Objectives: To determine the feasibility of dosing Haemate P® VWF/factor VIII (FVIII) concentrate based on pharmacokinetics (PK) in the management of surgical subjects with VWD. Methods: VWD subjects scheduled for elective surgery were enrolled in a prospective multicenter open-label cohort study. A pre-operative loading dose of VWF/FVIII concentrate based upon prior individual subject PK analysis was administered followed by postoperative therapeutic/ maintenance infusions. Results: Twenty-eight subjects with types 1, 2A or 3 VWD and one with type 2 M were enrolled. Median in vivo recovery of VWF ristocetin cofactor (VWF:RCo) was 1.9 IU dL-1 (IU kg-1) -1 with an interquartile range (IQR) of 1.6-2.5 IU dL-1 (IU kg-1)-1. Median response, half-life and clearance were 74.0% (IQR, 55.5-100%), 15.6h (IQR, 9.0-28.4h) and 3.26 mL kg-1 h-1 (IQR, 2.29-5.21mL kg-1 h-1), respectively. A PK-guided median VWF:RCo loading dose of 62.4 IU kg-1 (IQR, 50.1-87.0 IU kg-1) was administered. Postoperative mean trough VWF:RCo levels of 62-73 IU dL-1 were sufficient to prevent bleeding. Investigators rated hemostasis excellent or good in 96.3% of subjects on the day of surgery and 100% on the next day and on day 14. A subject with multiple risk factors developed pulmonary embolism, which resolved without sequelae. Conclusions: Haemate P® provided effective and safe hemostasis in VWD subjects undergoing elective surgery. Selection of Haemate® P loading dose on the basis of VWF PK proved feasible.

Original languageEnglish
Pages (from-to)1420-1430
Number of pages11
JournalJournal of Thrombosis and Haemostasis
Volume5
Issue number7
DOIs
Publication statusPublished - Jul 2007

Keywords

  • Factor VIII
  • Hereditary diseases
  • Postoperative hemorrhage
  • Prospective studies
  • Surgical hemostasis
  • Von Willebrand factor

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: A prospective multicenter trial in elective surgery'. Together they form a unique fingerprint.

Cite this